Cysteine-based 3-substituted 1, 5-benzoxathiepin derivatives: Two new classes of anti-proliferative agents
Resumen: Two distinct series of the 3-amino-1, 5-benzoxathiepin scaffold, derived from L-cysteine, were synthesized and evaluated for their anti-proliferative activity in the breast cancer MDA-MB-231 and MCF-7 cells, and in the ovarian carcinoma SKOV-3 cell line. (3R)-Amino-3, 4-dihydro-2H-1, 5-benzoxathiepin [(R)-10] was diversified into two forms: (a) by incorporating different amino acids at its position 3, through an amide bond; and (b) by construction of the purine ring to give 6-chloro-9-[2-(3, 4-dihydro-2H-1, 5-benzoxathiepin-(3R)-yl)]-9H-purine [(R)-28]. Nevertheless, when the introduction of iodine was tried at position 2 of the purine ring of (R)-28, 2-{[2-(6-chloro-2-iodo-9H-purin-9-yl) prop-2-en-1-yl] thio} phenol (34) was obtained. Compound 34 shows activity against cancer cells. Interestingly, 34 inhibits mammosphere formation at the micromolar range, demonstrating activity against cancer stem cells. Although further studies of its targets and mechanism of action are needed, these findings support the therapeutic potential of this compound in cancer.
Idioma: Inglés
DOI: 10.1016/j.arabjc.2017.01.011
Año: 2018
Publicado en: ARABIAN JOURNAL OF CHEMISTRY 11, 3 (2018), 426-441
ISSN: 1878-5352

Factor impacto JCR: 3.298 (2018)
Categ. JCR: CHEMISTRY, MULTIDISCIPLINARY rank: 59 / 172 = 0.343 (2018) - Q2 - T2
Factor impacto SCIMAGO: 0.605 - Chemistry (miscellaneous) (Q2) - Chemical Engineering (miscellaneous) (Q2)

Financiación: info:eu-repo/grantAgreement/ES/DGA/E40
Financiación: info:eu-repo/grantAgreement/ES/MINECO-FEDER/CTQ2013-40855-R
Tipo y forma: Article (Published version)
Área (Departamento): Área Química Orgánica (Dpto. Química Orgánica)
Exportado de SIDERAL (2019-12-12-10:05:42)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
articulos



 Notice créée le 2018-04-13, modifiée le 2019-12-12


Versión publicada:
 PDF
Évaluer ce document:

Rate this document:
1
2
3
 
(Pas encore évalué)